Castle Biosciences Stock Alpha and Beta Analysis
| CSTL Stock | USD 16.32 0.40 2.39% |
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as Castle Biosciences. It also helps investors analyze the systematic and unsystematic risks associated with investing in Castle Biosciences over a specified time horizon. Remember, high Castle Biosciences' alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to Castle Biosciences' market risk premium analysis include:
Beta 1 | Alpha (0.54) | Risk 2.71 | Sharpe Ratio (0.14) | Expected Return (0.37) |
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
Check out Castle Biosciences Backtesting, Castle Biosciences Valuation, Castle Biosciences Correlation, Castle Biosciences Hype Analysis, Castle Biosciences Volatility, Castle Biosciences History and analyze Castle Biosciences Performance. Castle Biosciences Market Premiums
Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. Castle Biosciences market risk premium is the additional return an investor will receive from holding Castle Biosciences long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Castle Biosciences. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate Castle Biosciences' performance over market.| α | -0.54 | β | 1.00 |
Castle Biosciences expected buy-and-hold returns
Although buy-and-hold investment strategy may not appeal to all investors, it may be used as a good measure of Castle Biosciences' Buy-and-hold return. Our buy-and-hold chart shows how Castle Biosciences performed over your current time horizon against a typical interest-earning bank account and a selected benchmark.Castle Biosciences Market Price Analysis
Market price analysis indicators help investors to evaluate how Castle Biosciences stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Castle Biosciences shares will generate the highest return on investment. By understating and applying Castle Biosciences stock market price indicators, traders can identify Castle Biosciences position entry and exit signals to maximize returns.
Castle Biosciences Return and Market Media
The median price of Castle Biosciences for the period between Thu, Apr 24, 2025 and Wed, Jul 23, 2025 is 18.75 with a coefficient of variation of 9.44. The daily time series for the period is distributed with a sample standard deviation of 1.74, arithmetic mean of 18.42, and mean deviation of 1.52. The Stock received a lot of media exposure during the period. Price Growth (%) |
| Timeline |
1 | Castle Biosciences First Quarter 2025 Earnings Revenues Beat Expectations, EPS Lags | 05/07/2025 |
2 | Acquisition by Cotton Rodney of 1952 shares of Castle Biosciences subject to Rule 16b-3 | 05/08/2025 |
3 | Disposition of tradable shares by Derek Maetzold of Castle Biosciences at 29.48 subject to Rule 16b-3 | 05/15/2025 |
4 | Castle Biosciences A Leading Player Among Top Nasdaq Stocks in Healthcare | 05/21/2025 |
5 | Acquisition by Harrison Miles of 13667 shares of Castle Biosciences subject to Rule 16b-3 | 05/22/2025 |
6 | Castle Biosciences Founder, President and CEO Derek Maetzold Honored with Prestigious Lifetime Achievement Award by The American Business Awards | 06/04/2025 |
7 | Virtual Meeting Scheduled for CSTL by Lake Street CSTL Stock News | 06/10/2025 |
8 | Castle Biosciences Chief Executive Officer Derek Maetzold to Participate in Panel Discussion During the 2025 BIO International Convention | 06/11/2025 |
9 | Castle Biosciences Enters Collaboration and License Agreement with SciBase to Develop Diagnostic Tests for Dermatologic Diseases | 06/16/2025 |
10 | Lake Street Reaffirms Their Buy Rating on Castle Biosciences - The Globe and Mail | 06/18/2025 |
11 | Disposition of 660 shares by Derek Maetzold of Castle Biosciences at 20.3 subject to Rule 16b-3 | 06/27/2025 |
12 | How did Castle Biosciences revenue and expenses trend in Q4 2024 - AInvest | 06/30/2025 |
13 | Castle Biosciences to Release Q2 2025 Financial Results and Host Conference Call on Aug. 4 - AInvest | 07/15/2025 |
14 | Castle Biosciences Honored with Multiple Top Workplaces Awards Recognizing the Companys Strong Culture | 07/17/2025 |
15 | Disposition of 267 shares by Derek Maetzold of Castle Biosciences at 27.51 subject to Rule 16b-3 | 07/22/2025 |
About Castle Biosciences Beta and Alpha
For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including Castle or other stocks. Alpha measures the amount that position in Castle Biosciences has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
| 2022 | 2023 | 2024 | 2025 (projected) | Payables Turnover | 6.77 | 4.38 | 8.72 | 9.16 | Days Of Inventory On Hand | 45.38 | 64.44 | 49.32 | 43.45 |
Castle Biosciences Upcoming Company Events
As portrayed in its financial statements, the presentation of Castle Biosciences' financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Castle Biosciences' leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of Castle Biosciences' public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of Castle Biosciences. Please utilize our Beneish M Score to check the likelihood of Castle Biosciences' management manipulating its earnings.
| 27th of February 2024 Upcoming Quarterly Report | View | |
| 1st of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 27th of February 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Build Portfolio with Castle Biosciences
Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.Build Diversified Portfolios
Align your risk with return expectations
Check out Castle Biosciences Backtesting, Castle Biosciences Valuation, Castle Biosciences Correlation, Castle Biosciences Hype Analysis, Castle Biosciences Volatility, Castle Biosciences History and analyze Castle Biosciences Performance. For more information on how to buy Castle Stock please use our How to buy in Castle Stock guide.You can also try the ETFs module to find actively traded Exchange Traded Funds (ETF) from around the world.
Castle Biosciences technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.